NeoSep1 Trial for Neonatal Sepsis
In July 2026, the NeoSep1 international clinical trial expanded to India, with the first newborn enrolled at JIPMER, Puducherry, to evaluate effective antibiotic combinations for treating drug-resistant neonatal sepsis.
- The trial is sponsored by the Global Antibiotic Research and Development Partnership (GARDP) in collaboration with international partners.
- The study evaluates safe, effective, and affordable antibiotic combinations for treating neonatal sepsis caused by antimicrobial-resistant (AMR) pathogens.
- Neonatal sepsis is a life-threatening bloodstream infection occurring in infants below 90 days of age, particularly premature and low-birth-weight ....
Do You Want to Read More?
Subscribe Now
Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Related Content
- 1 India Approves First Dengue Vaccine
- 2 WHO Lists First Ebola BDBV Diagnostic Test
- 3 Mission Drishti Encounters Anomaly After Solar Storm
- 4 ISRO Conducts Gaganyaan IMAT-05 Test
- 5 India Launches Once-Weekly Basal Insulin
- 6 White Rabbit-Based Indian Standard Time Distribution Network
- 7 World's Largest Synchronized Spintronic Network Demonstrated
- 8 CeNS Develops Ultra-Sensitive Ammonia Sensor
- 9 MOF Material Removes Tritium Efficiently
- 10 Indian Researchers Develop Placenta-on-Chip

